#IDMastodon #Viralimmunology #Drugdevelopment @asmicrobiology #Phase II #Clinicaltrial for evaluating the #antiviral activity, safety, efficacy, & #pharmacokinetics of #bemnifosbuvir in ambulatory patients with mild/moderate #COVID19 . Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause mortality. vs placebo
#IDMastodon #viralimmunology #DrugDevelopment #phase #clinicaltrial #Antiviral #pharmacokinetics #bemnifosbuvir #COVID19